HomeCompareLZAGF vs PLD

LZAGF vs PLD: Dividend Comparison 2026

LZAGF yields 1.10% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $5.86M in total portfolio value
10 years
LZAGF
LZAGF
● Live price
1.10%
Share price
$650.29
Annual div
$7.14
5Y div CAGR
45.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$8,733.09
Full LZAGF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — LZAGF vs PLD

📍 PLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLZAGFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LZAGF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LZAGF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LZAGF
Annual income on $10K today (after 15% tax)
$93.36/yr
After 10yr DRIP, annual income (after tax)
$7,423.13/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, PLD beats the other by $4,030,693.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LZAGF + PLD for your $10,000?

LZAGF: 50%PLD: 50%
100% PLD50/50100% LZAGF
Portfolio after 10yr
$2.98M
Annual income
$2,379,729.14/yr
Blended yield
79.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

LZAGF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.3
Piotroski
7/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LZAGF buys
0
PLD buys
0
No recent congressional trades found for LZAGF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLZAGFPLD
Forward yield1.10%3.10%
Annual dividend / share$7.14$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR45.9%74.4%
Portfolio after 10y$44.5K$5.91M
Annual income after 10y$8,733.09$4,750,725.19
Total dividends collected$22.1K$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: LZAGF vs PLD ($10,000, DRIP)

YearLZAGF PortfolioLZAGF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$10,860$160.25$11,241$540.96$381.00PLD
2$11,858$237.31$13,019$991.13$1.2KPLD
3$13,041$353.30$15,801$1,870.97$2.8KPLD
4$14,484$529.82$20,609$3,701.21$6.1KPLD
5$16,300$802.36$29,919$7,867.97$13.6KPLD
6$18,672$1,231.24$50,631$18,617.74$32.0KPLD
7$21,903$1,923.20$105,528$51,352.20$83.6KPLD
8$26,512$3,076.05$287,364$174,449.42$260.9KPLD
9$33,445$5,077.02$1,081,760$774,280.77$1.05MPLD
10$44,519$8,733.09$5,908,209$4,750,725.19$5.86MPLD

LZAGF vs PLD: Complete Analysis 2026

LZAGFStock

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

Full LZAGF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this LZAGF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LZAGF vs SCHDLZAGF vs JEPILZAGF vs OLZAGF vs KOLZAGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.